Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patie
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia
β Scribed by Maher Albitar; Steven J. Potts; Francis J. Giles; Susan O'Brien; Michael Keating; Deborah Thomas; Charlotte Clarke; Iman Jilani; Christine Aguilar; Elihu Estey; Hagop Kantarjian
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 221 KB
- Volume
- 106
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND: Interleukinβ15 (ILβ15) has been associated with the growth, survival and biological behavior of leukemic cells and response to therapy. We determined the expression of ILβ15 in lymphoblasts and evaluated its potential impact on the outcome in adult acute lymphoblastic le
## Abstract We evaluated the behavior of 38 children with standardβrisk and highβrisk acute lymphoblastic leukemia who received corticosteroids as part of their antileukemia chemotherapy. Each patient was assessed on two occasions: 16 weeks following remission and 1 year thereafter. Parent reports